Donald M. Lloyd-Jones

Feb 12, 2025 | jamanetwork.com | Donald M. Lloyd-Jones |Sadiya Khan |Maryanne Demasi |Rita F. Redberg

Statins for Primary Prevention of Cardiovascular Disease—Reply In Reply We thank Dr Demasi and colleagues for sharing their perspectives. We judge that the statements we made are supported by the evidence and we stand by the rationale presented and the conclusions expressed in our Viewpoint. As we discussed, data from randomized clinical trials show net benefit of statin therapy for patient groups with 10-year major cardiovascular event rates as low as 3%.

Jul 29, 2024 | jamanetwork.com | Sadiya Khan |Donald M. Lloyd-Jones

Statins for Primary Prevention of Cardiovascular Disease—With PREVENT, What’s a Clinician to Do? Quantitative decision tools are ubiquitous in medicine, assisting with diagnosis, prognosis, and treatment decisions. In cardiovascular disease (CVD) prevention, multivariable risk scores have been used for decades to align the intensity of prevention efforts with the absolute risk of a given patient.

Jan 30, 2024 | onlinelibrary.wiley.com | Gen-Min Lin |Donald M. Lloyd-Jones |Laura A. Colangelo |Joao Lima

Supporting Information Filename Description ejhf3155-sup-0001-Tables.docxWord 2007 document , 37.6 KB Appendix S1. Supporting Information. References 1, , , , , , et al.; Centers for Disease Control and Prevention (CDC). Vital signs: disparities in nonsmokers' exposure to secondhand smoke – United States, 1999-2012. MMWR Morb Mortal Wkly Rep 2015; 64: 103–108. 2, , , , .

Dec 28, 2023 | jamanetwork.com | Philip Greenland |Donald M. Lloyd-Jones |Sadiya Khan |Xiuqing Guo

Heart artery blockages start with cholesterol deposits, or plaques, that build up in the heart artery walls. Over time, these plaques can become hardened, or calcified. The calcium in plaques can be measured by a coronary computed tomographic scan. The scan takes 10 to 15 minutes and does not require any intravenous contrast or dye.

Nov 13, 2023 | healio.com | Katie Kalvaitis |Richard Smith |Steven Nissen |Donald M. Lloyd-Jones

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Lipoprotein(a) is a genetic risk factor for CVD, for which there are no treatments currently available. A single dose of lepodisiran was well-tolerated, safe and reduced Lp(a) more than 94% for nearly 1 year.